News

Immutep to Participate in the JMP Securities Life Sciences Conference

Media Release SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),…

2 years ago

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and…

2 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety…

2 years ago

Humacyte Announces Publication in Lancet Regional Health – Europe Presenting Use of Human Acellular Vessel™ (HAV™) to Treat Vascular Injuries in Ukraine

First regenerative medicine technology used in battlefield trauma Ukrainian surgeons trained on HAV procedures over video conferencing DURHAM, N.C., May…

2 years ago

CymaBay Names Harish Shantharam Chief Financial Officer

Proven Leader in Building Financial Organizations to Prepare Company for Successful Commercialization Planning for Seladelpar Launch as it Completes Development…

2 years ago

TriLink BioTechnologies Introduces Latest mRNA Capping Technology: CleanCap® M6 analog

Newest cap analog product improves mRNA potency with greater protein expression, offers time and cost savings, and streamlines manufacturing to…

2 years ago

Replimune to Participate in the Piper Sandler Spring Biopharma Symposium

WOBURN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the…

2 years ago

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results

Lead-in data from Phase 3 PEAK trial to be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual…

2 years ago

Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

IBSRELA provides meaningful reduction of multiple abdominal symptoms Patient-reported outcomes are strongly correlated with IBS-C abdominal symptom score WALTHAM, Mass.,…

2 years ago

Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology

The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive’s TCR discovery platformSEATTLE, May…

2 years ago